CY1115286T1 - Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson - Google Patents

Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson

Info

Publication number
CY1115286T1
CY1115286T1 CY20141100288T CY141100288T CY1115286T1 CY 1115286 T1 CY1115286 T1 CY 1115286T1 CY 20141100288 T CY20141100288 T CY 20141100288T CY 141100288 T CY141100288 T CY 141100288T CY 1115286 T1 CY1115286 T1 CY 1115286T1
Authority
CY
Cyprus
Prior art keywords
parkinson
toy
safinamide
treatment methods
disease treatment
Prior art date
Application number
CY20141100288T
Other languages
English (en)
Inventor
Fariello Ruggero
Carlo Cattaneo
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115286(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of CY1115286T1 publication Critical patent/CY1115286T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται νέες χρήσεις safinamide, παραγώγων safinamide και αναστολέων ΜΑΟ-Β σε νέους τύπους θεραπευτικής αγωγής της νόσου του Parkinson. Πλέον συγκεκριμένα η εφεύρεση αφορά μεθόδους για την θεραπευτική αγωγή της νόσου του Parkinson μέσω της χορήγησης safinamide, ενός παραγώγου safinamide ή ενός αναστολέα ΜΑΟ-Β σε συνδυασμό με άλλους θεραπευτικούς παράγοντες ή θεραπευτικές αγωγές της νόσου του Parkinson όπως levodopa/PDI ή αγωνιστές ντοπαμίνης.
CY20141100288T 2003-04-11 2014-04-15 Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson CY1115286T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
EP09154864.4A EP2070526B1 (en) 2003-04-11 2004-04-08 Methods for treatment of Parkinson's disease

Publications (1)

Publication Number Publication Date
CY1115286T1 true CY1115286T1 (el) 2017-01-04

Family

ID=33159845

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20091100857T CY1109295T1 (el) 2003-04-11 2009-08-12 Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
CY20141100288T CY1115286T1 (el) 2003-04-11 2014-04-15 Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson
CY2015025C CY2015025I2 (el) 2003-04-11 2015-07-01 Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100857T CY1109295T1 (el) 2003-04-11 2009-08-12 Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2015025C CY2015025I2 (el) 2003-04-11 2015-07-01 Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον

Country Status (28)

Country Link
US (3) US8283380B2 (el)
EP (2) EP1613296B1 (el)
JP (2) JP2006522800A (el)
KR (2) KR20110070929A (el)
CN (2) CN1771030A (el)
AR (1) AR044007A1 (el)
AT (1) ATE435012T1 (el)
AU (1) AU2004228782B2 (el)
BR (1) BRPI0409364A (el)
CA (1) CA2523188C (el)
CY (3) CY1109295T1 (el)
DE (1) DE602004021790D1 (el)
DK (2) DK1613296T3 (el)
ES (2) ES2454272T3 (el)
FR (1) FR15C0054I2 (el)
HU (1) HUS1500043I1 (el)
IL (2) IL171331A (el)
LU (1) LU92782I2 (el)
MX (1) MXPA05010873A (el)
NL (1) NL300752I2 (el)
NO (3) NO334316B1 (el)
NZ (1) NZ542910A (el)
PL (2) PL2070526T3 (el)
PT (2) PT2070526E (el)
RU (1) RU2342929C2 (el)
SI (2) SI1613296T1 (el)
TW (1) TWI340640B (el)
WO (1) WO2004089353A2 (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
EP1658062B1 (en) * 2003-08-25 2010-02-17 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CN101018546B (zh) * 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
SI1963280T1 (sl) * 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
EA017123B1 (ru) * 2006-06-19 2012-10-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
CA2684550A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US8519000B2 (en) 2007-06-15 2013-08-27 Newron Pharmaceuticals S.P.A. Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
HUE036232T2 (hu) 2007-12-11 2018-06-28 Newron Pharm Spa Eljárás nagy tisztasági fokú 2-[4-(3- vagy 2-fluorbenziloxi)-benzilamino]- propánamidok elõállítására
CN101903021B (zh) * 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
CA2723870C (en) * 2008-06-02 2015-04-21 Generics [Uk] Limited An improved process for the preparation of amines
CA2723869C (en) 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
EA021389B1 (ru) 2010-04-27 2015-06-30 Ньюрон Фармасьютикалс С.П.А. Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013081685A1 (en) 2011-08-19 2013-06-06 The Trustees Of Princeton University C-halogen bond formation
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
EA031621B1 (ru) 2012-11-02 2019-01-31 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
EP3013342B1 (en) 2013-06-27 2021-04-14 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP3831375A1 (en) * 2014-04-21 2021-06-09 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
CN106795098B (zh) * 2014-10-02 2020-07-14 默加拜奥伍德有限公司 α-氨基酰胺衍生化合物及包含其的药物组合物
MX2018002255A (es) * 2015-08-27 2018-06-06 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa.
EP3429569A4 (en) * 2016-03-17 2020-02-26 The Johns Hopkins University METHODS FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY FARNESYLATION DE PARIS
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USING HUMAN EXCREMENTS AND SECRETS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
BR112020008653A2 (pt) 2017-11-02 2020-10-27 Zambon S.P.A. composições farmacêuticas compreendendo safinamida
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
EP4203939A1 (en) * 2020-08-31 2023-07-05 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
JP2736103B2 (ja) 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
PT828513E (pt) * 1995-05-26 2004-05-31 Pfizer Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
PT2070526E (pt) 2014-03-31
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
JP2006522800A (ja) 2006-10-05
IL171331A (en) 2012-03-29
JP2013067647A (ja) 2013-04-18
EP1613296B1 (en) 2009-07-01
SI2070526T1 (sl) 2014-05-30
PL1613296T3 (pl) 2009-12-31
PL2070526T3 (pl) 2014-08-29
US8901176B2 (en) 2014-12-02
CY2015025I1 (el) 2016-04-13
ATE435012T1 (de) 2009-07-15
KR101129015B1 (ko) 2012-04-20
NL300752I2 (el) 2016-07-05
EP2070526B1 (en) 2014-02-26
RU2005131422A (ru) 2006-04-27
WO2004089353A3 (en) 2004-12-16
ES2326373T3 (es) 2009-10-08
TW200505423A (en) 2005-02-16
NO335537B1 (no) 2014-12-22
US8283380B2 (en) 2012-10-09
CN1771030A (zh) 2006-05-10
CY1109295T1 (el) 2014-07-02
DK2070526T3 (da) 2014-03-24
KR20060010745A (ko) 2006-02-02
WO2004089353A2 (en) 2004-10-21
PT1613296E (pt) 2009-07-30
KR20110070929A (ko) 2011-06-24
NO2015018I1 (no) 2015-08-03
IL216403A0 (en) 2011-12-29
IL216403A (en) 2015-01-29
NO20131417L (no) 2005-12-09
CN102274517A (zh) 2011-12-14
NO20054640D0 (no) 2005-10-10
MXPA05010873A (es) 2006-03-21
US9492410B2 (en) 2016-11-15
NZ542910A (en) 2007-10-26
CN102274517B (zh) 2018-08-31
US20150150833A1 (en) 2015-06-04
CA2523188C (en) 2012-09-25
NO334316B1 (no) 2014-02-03
NO2015018I2 (no) 2015-07-23
AU2004228782B2 (en) 2010-05-20
LU92782I2 (fr) 2015-09-22
DE602004021790D1 (de) 2009-08-13
ES2454272T3 (es) 2014-04-10
WO2004089353A8 (en) 2005-09-01
DK1613296T3 (da) 2009-10-05
SI1613296T1 (sl) 2009-10-31
RU2342929C2 (ru) 2009-01-10
AU2004228782A1 (en) 2004-10-21
BRPI0409364A (pt) 2006-04-25
US20130053368A1 (en) 2013-02-28
CY2015025I2 (el) 2016-04-13
AR044007A1 (es) 2005-08-24
TWI340640B (en) 2011-04-21
CA2523188A1 (en) 2004-10-21
FR15C0054I1 (fr) 2015-11-09
EP2070526A1 (en) 2009-06-17
HUS1500043I1 (hu) 2018-11-28
EP1613296A2 (en) 2006-01-11
FR15C0054I2 (fr) 2018-01-26

Similar Documents

Publication Publication Date Title
CY1115286T1 (el) Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson
CY1124931T1 (el) Αντιμετωπιση της φαινυλκετονουριας με bh4
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
CY1119480T1 (el) Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων για τη θεραπευτικη αντιμετωπιση διαταραχων της ορασης
TR201907874T4 (tr) Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler.
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
NO20033665L (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
CO2022000270A2 (es) Inhibidores de enzimas